Olympus (OTCMKTS:OCPNY – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Olympus and NexGel, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
| NexGel | 1 | 2 | 0 | 0 | 1.67 |
NexGel has a consensus price target of $40.00, indicating a potential upside of 838.97%. Given NexGel’s higher probable upside, analysts clearly believe NexGel is more favorable than Olympus.
Volatility & Risk
Olympus has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, NexGel has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Valuation and Earnings
This table compares Olympus and NexGel”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Olympus | $7.74 billion | 2.99 | $1.03 billion | $0.82 | 21.95 |
| NexGel | $12.07 million | 0.17 | -$3.00 million | ($14.20) | -0.30 |
Olympus has higher revenue and earnings than NexGel. NexGel is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.0% of Olympus shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 19.8% of NexGel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Olympus and NexGel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Olympus | 13.80% | 24.30% | 9.30% |
| NexGel | -51.26% | -121.18% | -41.15% |
Summary
Olympus beats NexGel on 10 of the 14 factors compared between the two stocks.
About Olympus
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
